Quality Reports
Breast Cancer Performance Rates
Colorectal Cancer Performance Rates
Allogenic Bone Marrow Transplant Data
Yale Cancer Center Outcomes Reporting
Patients face an increasingly complex decision when deciding where to go for their cancer treatment. There are several factors that can aid in that decision-making process including location, center designation, physician experience, physician referral, health plan coverage, and options for treatment. In addition to these factors, nationally accepted quality measures, outcome data, and patient satisfaction information can also be helpful tools in comparisons between cancer treatment centers or hospitals.
ACSO/NCCN Quality Measures
Yale Cancer Center and our partner, Smilow Cancer Hospital at Yale-New Haven, acknowledge the seven American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) evidence-based quality guidelines for breast and colorectal cancers. The latest performance data for the Breast Cancer Program and Gastrointestinal Cancers Program in the treatment of these diseases is listed below.
Learn More >>
Breast Cancer Performance Rates
Performance Measure |
2004 |
2005 |
2006 |
2007 |
2008 |
Hormone Therapy (HT)1 |
49% |
53% |
60% |
94% |
90% |
Radiation Therapy (RT)2 |
73% |
86% |
84% |
98% |
96% |
Combination Therapy (MAC)3 |
71% |
80% |
77% |
83% |
91% |
- Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year of diagnosis for women with T1c N0 M0, or sate II or III ERA and/or PRA positive breast cancer.
- Radiation therapy is administered within 1 year of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer.
- Combination chemotherapy is considered or administered within 4 months of diagnosis for women under age 70 with T1c N0 M0, or stafe II or III ERA and PRA negative breast cancer.
Colorectal Cancer Performance Rates
Performance Measure |
2004 |
2005 |
2006 |
2007 |
2008 |
Adjuvant Chemotherapy (C/CT)1 |
80% |
88% |
73% |
88% |
100% |
12 Regional Lymph Nodes (C/12RLN)2 |
89% |
88% |
90% |
91% |
95% |
Adjuvant Radiation Therapy (R/RT)3 |
100% |
80% |
83% |
100% |
100% |
Postoperative Adjuvant Chemotherapy Therapy (R/CT)4 |
|
|
50% |
89% |
88% |
- Adjuvant chemotherapy is considered or administered within 4 months of diagnosis for patients under the age of 80 with stage III (lymph node positive) colon cancer.
- At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.
- Radiation therapy is considered or administered within 6 months of diagnosis for patients under the age of 80 with clinical or pathologic T4N1M0 or stage III colorectal cancer after receiving surgical resection for rectal cancer.
- Postoperative adjuvant chemotherapy is administered within 9 months (270 days) of diagnosis to patients under the age of 80 with clinical or pathologic AJCC Stage II or Stage III receiving surgical resection for rectal cancer.
NMDP Allogeneic Bone Marrow Transplant Center Data
The National Marrow Donor Program tracks data on patients who have received a transplant at accredited United States Transplant Centers. Yale Cancer Center’s actual results are above the predicted survival range. National one-year actual survival is 54% for the 8,847 patients transplanted in the United States last year.
Learn More >>
Institution |
Number of Patients |
Disease Severity * |
One-Year Survival |
Predicted Survival |
95% Confidence Interval |
Yale |
84 |
3 |
67% |
58% |
39 – 64% |
The following chart shows how Yale Cancer Center compares to Transplant Centers in the United States Reporting More than 50 Allogeneic Transplants During the Last Reporting Period (2002 – 2007):
Institution |
Number of Patients |
Disease Severity * |
One-Year Survival |
Predicted Survival |
Yale Univeristy/Yale-New Haven Hospital |
84 |
3 |
67.00% |
58.00% |
B |
96 |
3 |
67.00% |
55.00% |
C |
132 |
2 |
67.00% |
60.00% |
D |
365 |
3 |
66.00% |
57.00% |
E |
242 |
3 |
66.00% |
56.00% |
F |
187 |
1 |
66.00% |
66.00% |
G |
190 |
2 |
65.00% |
62.00% |
H |
362 |
4 |
64.00% |
53.00% |
I |
104 |
2 |
62.00% |
61.00% |
J |
69 |
1 |
62.00% |
66.00% |
K |
218 |
2 |
61.00% |
60.00% |
L |
155 |
2 |
61.00% |
60.00% |
M |
87 |
3 |
60.00% |
57.00% |
N |
520 |
3 |
60.00% |
57.00% |
O |
136 |
2 |
60.00% |
58.00% |
P |
311 |
3 |
59.00% |
57.00% |
Q |
106 |
3 |
59.00% |
56.00% |
R |
77 |
4 |
58.00% |
52.00% |
S |
523 |
4 |
57.00% |
52.00% |
T |
68 |
3 |
57.00% |
55.00% |
U |
96 |
2 |
57.00% |
59.00% |
V |
239 |
5 |
56.00% |
49.00% |
W |
100 |
4 |
56.00% |
53.00% |
X |
167 |
3 |
56.00% |
56.00% |
Y |
108 |
2 |
56.00% |
59.00% |
Z |
77 |
2 |
54.00% |
59.00% |
AA |
104 |
4 |
53.00% |
55.00% |
BB |
190 |
3 |
53.00% |
57.00% |
CC |
167 |
3 |
53.00% |
55.00% |
DD |
85 |
5 |
52.00% |
51.00% |
EE |
117 |
5 |
52.00% |
50.00% |
FF |
127 |
4 |
51.00% |
54.00% |
GG |
99 |
4 |
51.00% |
53.00% |
HH |
134 |
4 |
51.00% |
53.00% |
II |
228 |
4 |
51.00% |
53.00% |
JJ |
57 |
4 |
51.00% |
52.00% |
KK |
70 |
2 |
51.00% |
59.00% |
LL |
65 |
5 |
50.00% |
51.00% |
MM |
88 |
5 |
49.00% |
48.00% |
NN |
207 |
4 |
49.00% |
54.00% |
OO |
46 |
5 |
48.00% |
51.00% |
PP |
63 |
4 |
48.00% |
55.00% |
56 |
5 |
46.00% |
51.00% |
|
RR |
67 |
3 |
46.00% |
58.00% |
SS |
66 |
5 |
45.00% |
49.00% |
TT |
88 |
4 |
43.00% |
54.00% |
UU |
123 |
5 |
41.00% |
49.00% |
VV |
93 |
5 |
41.00% |
46.00% |
WW |
69 |
4 |
41.00% |
52.00% |
XX |
96 |
5 |
37.00% |
49.00% |
YY |
76 |
4 |
37.00% |
51.00% |
* Disease Severity refers to the overall disease condition of patients and is a measure of patients' pre-transplant health characteristics that predict survival after transplantation. The risk categories, based on overall disease condition of treated patients, are measured on a scale from 1 (low risk) to 5 (high risk).